| Characteristics . | Value . |
|---|---|
| Age, yr | |
| n | 32 |
| Median (range) | 62.0 (34–81) |
| Gender, n (%) | |
| Female | 18 (56) |
| Male | 14 (44) |
| Race, n (%) | |
| White | 24 (75) |
| Black or African American | 3 (9) |
| Asian | 3 (9) |
| Unknown | 1 (3) |
| Other | 1 (3) |
| ECOG performance status, n (%) | |
| 0 | 15 (47) |
| 1 | 17 (53) |
| Disease diagnosis, n (%) | |
| Breast carcinoma | 13 (41) |
| Colorectal carcinoma | 8 (25) |
| Non-small cell lung cancer | 7 (22) |
| Squamous cell carcinoma of head and neck | 2 (6) |
| Urothelial carcinoma | 2 (6) |
| Gastric/gastroesophageal adenocarcinoma | 0 |
| Time since diagnosis, mo | |
| n | 30 |
| Median (range) | 54.4 (9–168) |
| Tumor spread, n (%) | |
| Metastatic | 30 (94) |
| Locally advanced | 2 (6) |
| Disease status | |
| Refractory | 29 (91) |
| Relapsed | 3 (9) |
| Prior therapiesa | |
| Systemicb | 32 (100) |
| Radiation | 26 (81) |
| Surgery | 22 (69) |
| Checkpoint inhibitor | 8 (25) |
| Characteristics . | Value . |
|---|---|
| Age, yr | |
| n | 32 |
| Median (range) | 62.0 (34–81) |
| Gender, n (%) | |
| Female | 18 (56) |
| Male | 14 (44) |
| Race, n (%) | |
| White | 24 (75) |
| Black or African American | 3 (9) |
| Asian | 3 (9) |
| Unknown | 1 (3) |
| Other | 1 (3) |
| ECOG performance status, n (%) | |
| 0 | 15 (47) |
| 1 | 17 (53) |
| Disease diagnosis, n (%) | |
| Breast carcinoma | 13 (41) |
| Colorectal carcinoma | 8 (25) |
| Non-small cell lung cancer | 7 (22) |
| Squamous cell carcinoma of head and neck | 2 (6) |
| Urothelial carcinoma | 2 (6) |
| Gastric/gastroesophageal adenocarcinoma | 0 |
| Time since diagnosis, mo | |
| n | 30 |
| Median (range) | 54.4 (9–168) |
| Tumor spread, n (%) | |
| Metastatic | 30 (94) |
| Locally advanced | 2 (6) |
| Disease status | |
| Refractory | 29 (91) |
| Relapsed | 3 (9) |
| Prior therapiesa | |
| Systemicb | 32 (100) |
| Radiation | 26 (81) |
| Surgery | 22 (69) |
| Checkpoint inhibitor | 8 (25) |
a Subjects who received the same type of therapy multiple times were counted once for that type of therapy.
b Checkpoint inhibitors were excluded.
Abbreviation: ECOG, Eastern Cooperative Oncology Group.
| Characteristics . | Value . |
|---|---|
| Age, yr | |
| n | 32 |
| Median (range) | 62.0 (34–81) |
| Gender, n (%) | |
| Female | 18 (56) |
| Male | 14 (44) |
| Race, n (%) | |
| White | 24 (75) |
| Black or African American | 3 (9) |
| Asian | 3 (9) |
| Unknown | 1 (3) |
| Other | 1 (3) |
| ECOG performance status, n (%) | |
| 0 | 15 (47) |
| 1 | 17 (53) |
| Disease diagnosis, n (%) | |
| Breast carcinoma | 13 (41) |
| Colorectal carcinoma | 8 (25) |
| Non-small cell lung cancer | 7 (22) |
| Squamous cell carcinoma of head and neck | 2 (6) |
| Urothelial carcinoma | 2 (6) |
| Gastric/gastroesophageal adenocarcinoma | 0 |
| Time since diagnosis, mo | |
| n | 30 |
| Median (range) | 54.4 (9–168) |
| Tumor spread, n (%) | |
| Metastatic | 30 (94) |
| Locally advanced | 2 (6) |
| Disease status | |
| Refractory | 29 (91) |
| Relapsed | 3 (9) |
| Prior therapiesa | |
| Systemicb | 32 (100) |
| Radiation | 26 (81) |
| Surgery | 22 (69) |
| Checkpoint inhibitor | 8 (25) |
| Characteristics . | Value . |
|---|---|
| Age, yr | |
| n | 32 |
| Median (range) | 62.0 (34–81) |
| Gender, n (%) | |
| Female | 18 (56) |
| Male | 14 (44) |
| Race, n (%) | |
| White | 24 (75) |
| Black or African American | 3 (9) |
| Asian | 3 (9) |
| Unknown | 1 (3) |
| Other | 1 (3) |
| ECOG performance status, n (%) | |
| 0 | 15 (47) |
| 1 | 17 (53) |
| Disease diagnosis, n (%) | |
| Breast carcinoma | 13 (41) |
| Colorectal carcinoma | 8 (25) |
| Non-small cell lung cancer | 7 (22) |
| Squamous cell carcinoma of head and neck | 2 (6) |
| Urothelial carcinoma | 2 (6) |
| Gastric/gastroesophageal adenocarcinoma | 0 |
| Time since diagnosis, mo | |
| n | 30 |
| Median (range) | 54.4 (9–168) |
| Tumor spread, n (%) | |
| Metastatic | 30 (94) |
| Locally advanced | 2 (6) |
| Disease status | |
| Refractory | 29 (91) |
| Relapsed | 3 (9) |
| Prior therapiesa | |
| Systemicb | 32 (100) |
| Radiation | 26 (81) |
| Surgery | 22 (69) |
| Checkpoint inhibitor | 8 (25) |
a Subjects who received the same type of therapy multiple times were counted once for that type of therapy.
b Checkpoint inhibitors were excluded.
Abbreviation: ECOG, Eastern Cooperative Oncology Group.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
